The Protective Effect of Dietary EPA‐Enriched Ethanolamine Plasmalogens Against Hyperlipidemia in Aged Mice
Lin Ding,Lingyu Zhang,Haohao Shi,Changhu Xue,Teruyoshi Yanagita,Tiantian Zhang,Yuming Wang
DOI: https://doi.org/10.1002/ejlt.202000179
2020-01-01
European Journal of Lipid Science and Technology
Abstract:Decreased ethanolamine plasmalogen (PlsEtn) levels are observed in erythrocytes from patients with hyperlipidemia. Dietary PlsEtns can increase erythrocyte membrane PlsEtns and decrease plasma cholesterol; however, they do not affect triacylglycerol levels. In the present study, the effects of eicosapentaenoic acid-enriched PlsEtn (EPA-PlsEtn) on hyperlipidemia are evaluated in comparison to those of EPA-enriched phosphatidylcholine (EPA-PC) in senescence-accelerated mice (SAMP8). The results indicate that EPA-PlsEtn supplementation dramatically reduces triacylglycerol (42%,p< 0.01) and serum cholesterol (32%,p< 0.05) levels compared to those in the model group, while EPA-PC treatment does not significantly affect either of these parameters. Mechanistically, the triacylglycerol-lowering effect of EPA-PlsEtn may be attributed to accelerated fatty acid beta-oxidation that occurs due to the upregulation of carnitine palmitoyl transferase (CPT)-1a, CPT-2, and acyl-CoA oxidase 1 expression. Additionally, EPA-PlsEtn supplementation can reduce hepatic cholesterol levels via promoting cholesterol efflux mediated by ATP binding cassette subfamily G member 5 and the synthesis of bile acids regulated by farnesoid X receptor. These findings suggest that EPA-PlsEtn may be promising for use as a novel therapeutic agent for the treatment of age-related hyperlipidemia and metabolic disorder. Practical Applications: Supplementary EPA-PlsEtn can reduce both cholesterol and triacylglycerol levels in the serum and liver of SAMP8 mice, which contributes to the protection against age-related hyperlipidemia. EPA-PlsEtn supplementation accelerates hepatic fatty acid beta-oxidation and cholesterol efflux, which results in lowering serum lipid levels. EPA-PlsEtn and EPA-PC exert different effects on lipid metabolism via different metabolic pathways, which indicates the activity-structure relationship is worth further investigation.